Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
1. MRK reported Q3 earnings and revenue exceeding estimates, driven by Keytruda. 2. Keytruda sales reached over $8 billion, marking a 10% rise year-over-year. 3. Merck narrowed its 2025 earnings outlook to $8.93-$8.98 per share. 4. Gardasil sales fell 24% due to low demand in China. 5. Merck's net income increased to $5.79 billion from $3.16 billion year-on-year.